April 22, 2024 News by Marisa Wexler, MS AAN 2024: Briumvi found to ease disability in certain MS patients Two years of treatment with Briumvi (ublituximab) in clinical trials resulted in a confirmed reduction in disability for more than 1 in 10 people with early relapsing multiple sclerosis (MS) who had not received any prior treatment.
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Earlier Ocrevus lowers MS progression risk over 10 years Ocrevus (ocrelizumab) continued to prevent disability progression among people with relapsing and progressive forms of multiple sclerosis (MS) over 10 years, according to clinical trial analyses. The most pronounced benefits were observed in patients who started on…
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS For people recently diagnosed with multiple sclerosis (MS), first-line treatment with Kesimpta (ofatumumab) was associated with a lower risk of disability progression over starting it after about 2.5 years of using Aubagio (teriflunomide). Thatās according to…
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8 Long-term treatment with Clene Nanomedicine‘s experimental oral therapy CNM-Au8 led to signs of sustained improvements in nerve and myelin health for people with relapsing-remitting multiple sclerosis (RRMS) over three years, according to new data from the…
April 18, 2024 News by Lindsey Shapiro, PhD AAN 2024: Ocrevus benefits Black, Hispanic patients same as whites Ocrevus (ocrelizumab) had similar benefits in Black and Hispanic multiple sclerosis (MS) patients as earlier clinical trials with white patients did, one-year data from the CHIMES clinical trial indicates. About half of the CHIMES participants achieved no…
April 17, 2024 News by Marisa Wexler, MS AAN 2024: Fertility treatment in MS doesn’t increase relapse risk Undergoing fertility treatment with assistive reproductive technologies does not increase the likelihood of having a relapse for women with multiple sclerosis (MS) who are taking a disease-modifying therapy (DMT), according to a new analysis. “The results are…